Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;79(Spec 6/1):576-581.

[New progress in the treatment of locally advance pancreatic cancer]

[Article in Spanish]
Martín de Santibañes  1 , Rodrigo Sanchez Clariá  2 , Eduardo de Santibañes  3 , Juan Pekolj  3 , Oscar Mazza  2
Affiliations
  • PMID: 31864229
Free article
Review

[New progress in the treatment of locally advance pancreatic cancer]

[Article in Spanish]
Martín de Santibañes et al. Medicina (B Aires). 2019.
Free article

Abstract
in English, Spanish

Locally advanced pancreatic cancer (LAPC) has several definitions, but it is essentially a non-metastatic tumor, in which the initial surgical resection is not considered beneficial due to the extensive vascular involvement and consequent high chance of a nonradical resection. The introduction of chemotherapy with calcium leucovorin, fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX) and gemcitabine-nab (nanoparticle albumin-bound)-paclitaxel (gem-nab) had very important implications for the management of patients with LAPC. After 4 to 6 months of induction chemotherapy, a large proportion of them have stable disease or even tumor regression, allowing to rescue those who initially were not candidates for surgery, with 30-35 months overall survival after surgery.

El cáncer de páncreas localmente avanzado (CPLA) tiene varias definiciones, pero esencialmente es un tumor no metastásico, en el que la resección quirúrgica inicial no se considera beneficiosa debido a la extensa afectación vascular y la alta probabilidad de tener márgenes quirúrgicos con compromiso tumoral. La introducción de la quimioterapia con leucovorina cálcica, fluorouracilo, clorhidrato de irinotecán y oxaliplatino (FOLFIRINOX) y gemcitabina-nab-paclitaxel (paclitaxel acoplado a albúmina, lo que aumenta su solubilidad) ha tenido alcances muy importantes en el tratamiento de pacientes con CPLA. Después de 4 a 6 meses de quimioterapia de inducción, una gran proporción tiene enfermedad estable o incluso regresión tumoral, permitiendo rescatarlos quirúrgicamente, que de inicio no eran candidatos a una cirugía resectiva, con una supervivencia global de 30 a 35 meses.

Keywords: FOLFIRINOX; locally advance pancreatic cancer; neoadjuvant chemotherapy; radiotherapy; surgery.

PubMed Disclaimer

MeSH terms